Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation

OBJECTIVE: The use of Durvalumab following chemoradiotherapy in patients with stage III NSCLC, considerably increased PFS (progression free survival) and OS (overall survival). Unfortunately, Durvalumab is currently not reimbursed for this indication in Lebanon so far. We have used Atezolizumab on a...

Descripción completa

Detalles Bibliográficos
Autores principales: Saade, Lili Jose, Tfayli, Arafat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334090/
https://www.ncbi.nlm.nih.gov/pubmed/36974525
http://dx.doi.org/10.31557/APJCP.2023.24.3.737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334090/
https://www.ncbi.nlm.nih.gov/pubmed/36974525
http://dx.doi.org/10.31557/APJCP.2023.24.3.737

Ejemplares similares